Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer

Marketa Hermanova, Petr Karasek, Jiri Tomasek, Jiri Lenz, Jiri Jarkovsky, Petr Dite

. 2010 ; 16 (15) : 1879-1884.

Jazyk angličtina Země Tchaj-wan

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12025786

Grantová podpora
NR9295 MZ0 CEP - Centrální evidence projektů

AIM: To perform a comparative analysis of clinicopathological correlations of cyclooxygenase-2 (COX-2) expression in pancreatic cancer, examined by monoclonal and polyclonal antibodies. METHODS: The COX-2 expression in 85 resection specimens of pancreatic ductal adenocarcinoma was immunohistochemically examined using both monoclonal and polyclonal antibodies. The final immunoscores were obtained by multiplying the percentage of positive cells with the numeric score reflecting the staining intensity. COX-2 expression levels were classified into three categories (0, 1+, and 2+) and the clinicopathological correlations were statistically evaluated and analyzed. RESULTS: The positive tumor expression rates of COX-2 were 80.5% using monoclonal antibody and 69.4% using polyclonal antibody. In the Kaplan-Meier analysis, no significant correlations were found between levels of COX-2 expression and overall survival (OS), but trends to longer OS were found in COX-2 negative cases using monoclonal antibody. Significantly longer disease free survival was revealed in COX-2 negative cases using monoclonal antibody (P = 0.019). No correlations between COX-2 expression levels and grade (G), tumor (T) status and nodal (N) status were demonstrated. Low histological grade showed a strong association with a longer OS (P < 0.001). Correlation of survival and T status revealed a shorter OS in T3 tumors, but the results reached only marginal statistical significance (P = 0.070). In the multivariate Cox proportional hazards regression model, histological grade, T and N status remained valuable predictors of a worse survival with borderline significance for T [hazards ratio (HR) = 4.18 for G (if G = 3, P < 0.001); HR = 1.64 for T (if T = 3, P = 0.065); HR = 2.53 for N (if N = 1, P = 0.006)]. Higher grade, T or N status was associated with a worse OS. CONCLUSION: The immunohistochemically assessed level of COX-2 expression does not seem to represent a valuable independent prognostic factor and is not superior to the conventional prognostic factors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025786
003      
CZ-PrNML
005      
20200429134614.0
007      
ta
008      
120817s2010 ch f 000 0#eng||
009      
AR
024    7_
$a 10.3748/wjg.v16.i15.1879 $2 doi
035    __
$a (PubMed)20397266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ch
100    1_
$a Hermanová, Markéta $7 xx0073982 $u First Department of Pathologic Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic. marketa.hermanova@fnusa.cz
245    10
$a Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer / $c Marketa Hermanova, Petr Karasek, Jiri Tomasek, Jiri Lenz, Jiri Jarkovsky, Petr Dite
520    9_
$a AIM: To perform a comparative analysis of clinicopathological correlations of cyclooxygenase-2 (COX-2) expression in pancreatic cancer, examined by monoclonal and polyclonal antibodies. METHODS: The COX-2 expression in 85 resection specimens of pancreatic ductal adenocarcinoma was immunohistochemically examined using both monoclonal and polyclonal antibodies. The final immunoscores were obtained by multiplying the percentage of positive cells with the numeric score reflecting the staining intensity. COX-2 expression levels were classified into three categories (0, 1+, and 2+) and the clinicopathological correlations were statistically evaluated and analyzed. RESULTS: The positive tumor expression rates of COX-2 were 80.5% using monoclonal antibody and 69.4% using polyclonal antibody. In the Kaplan-Meier analysis, no significant correlations were found between levels of COX-2 expression and overall survival (OS), but trends to longer OS were found in COX-2 negative cases using monoclonal antibody. Significantly longer disease free survival was revealed in COX-2 negative cases using monoclonal antibody (P = 0.019). No correlations between COX-2 expression levels and grade (G), tumor (T) status and nodal (N) status were demonstrated. Low histological grade showed a strong association with a longer OS (P < 0.001). Correlation of survival and T status revealed a shorter OS in T3 tumors, but the results reached only marginal statistical significance (P = 0.070). In the multivariate Cox proportional hazards regression model, histological grade, T and N status remained valuable predictors of a worse survival with borderline significance for T [hazards ratio (HR) = 4.18 for G (if G = 3, P < 0.001); HR = 1.64 for T (if T = 3, P = 0.065); HR = 2.53 for N (if N = 1, P = 0.006)]. Higher grade, T or N status was associated with a worse OS. CONCLUSION: The immunohistochemically assessed level of COX-2 expression does not seem to represent a valuable independent prognostic factor and is not superior to the conventional prognostic factors.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x metabolismus $7 D000911
650    _2
$a cyklooxygenasa 2 $x biosyntéza $7 D051546
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese enzymů $7 D015971
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a vývody pankreatu $x enzymologie $x patologie $7 D010183
650    _2
$a nádory slinivky břišní $x enzymologie $x chirurgie $7 D010190
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Karásek, Petr $7 xx0128590 $u Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Tomášek, Jiří $7 xx0107945 $u Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1#
$a Lenz, Jiří. $7 xx0179491 $u First Department of Pathologic Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Jarkovský, Jiří, $d 1976- $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic $7 stk2008461294
700    1_
$a Dítě, Petr, $d 1941- $7 jn20000400604 $u Department of Gastroenterology, Medical Faculty of Masaryk University and The Faculty Hospital, Brno, Czech Republic
773    0_
$w MED00006918 $t World journal of gastroenterology WJG $x 1007-9327 $g Roč. 16, č. 15 (2010), s. 1879-1884
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20397266 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20200429134608 $b ABA008
999    __
$a ok $b bmc $g 947828 $s 783132
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 16 $c 15 $d 1879-1884 $i 1007-9327 $m World journal of gastroenterology $n World J Gastroenterol $x MED00006918
GRA    __
$a NR9295 $p MZ0
LZP    __
$a Pubmed-20120817/10/03

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...